RESEARCH AND DEVELOPMENT COLLABORATION AND OPTION AGREEMENTDevelopment Collaboration and Option Agreement • March 14th, 2024 • Molecular Partners Ag • Biological products, (no disgnostic substances)
This Research and Development Collaboration and Option Agreement (this “Agreement”) is made and entered into effective as of 5 January 2024 (the “Effective Date”) by and between Orano Med, a French simplified joint-stock company, with registered office at 125 avenue de Paris, 92320 Chatillon, France (“Orano Med”), and Molecular Partners, a Swiss corporation, with registered office at Wagistrasse 14, 8952 Schlieren, Switzerland (“Molecular Partners”). Molecular Partners and Orano Med may be referred to herein individually as a “Party” or collectively as the “Parties”.
